ClinicalTrials.gg
TerminatedNCT04680975dcSSCUpdated Jun 5, 2023Results posted

Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis

A Phase 2 interventional study of Belumosudil in Diffuse Cutaneous Systemic Sclerosis, sponsored by Kadmon, a Sanofi Company. Terminated at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-05.

Sponsored by Kadmon, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decision due to slow enrollment and strategic consideration; not driven by any safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 153 studies in Scleroderma, Diffuse with a site in United States — 29 open to participants now, 39 under way, 5 of them phase 3. Scleroderma, Diffuse · United States.

Enrollment
89th of 120
10 · median 29
Started
2021
with 9 others
Phase 2
41 of 153
8 open now
Registered
109th of 153
by date

Among the 153 studies in Scleroderma, Diffuse with a site in United States, this one is the 89th largest by enrollment of the 120 interventional ones that give a count, is one of 10 that started in 2021, is one of 41 in phase 2, and was the 109th registered.

Scleroderma, Diffuse

310 studies on the registry are indexed under Scleroderma, Diffuse; 76 are open to participants now.

Browse Scleroderma, Diffuse studies →

Open to participants now

29 of the 153 studies in Scleroderma, Diffuse with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 55 Scleroderma, Diffuse studies recruiting now, 28 (51%) set no upper age limit and 20 (36%) stop at 75 or younger; 10 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 153 studies in Scleroderma, Diffuse with a site in United States, or all of them as a file.
02

Study summary

This was a phase 2, open-label, single-cohort, multicenter trial of belumosudil in participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc). An estimated total of 12 to 15 participants would receive belumosudil 200 milligrams (mg) administered orally (PO) twice daily (BID) for 52 weeks. The primary analysis was at 24 weeks.

Read the detailed description

The primary objective of this phase 2, open-label, single-cohort, multicenter trial was to evaluate the efficacy of belumosudil 200 mg BID using the Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) after 24 weeks of therapy. The duration of the study was approximately 14 months (4 weeks for screening, 52 weeks of dosing period, and 4 weeks of Follow-up)

Participants who had signed an Institutional Review Board/Independent Ethics Committee-(IRB/IEC)-approved informed consent form (ICF) and met all of the inclusion/exclusion criteria were enrolled. A total of 10 participants at 6 sites received belumosudil 200 mg in tablet form administered PO BID for 52 weeks. The total duration of the study is approximately 14 months: a 4-week screening period, a 52-week treatment period, and a 4-week follow-up.

The primary endpoint was analyzed using Week 24 data.

Efficacy was assessed throughout the 52-week dosing period using:

  • Composite Response Index in Systemic Sclerosis (CRISS)
  • Modified Rodnan Skin Score (mRSS)
  • Pulmonary Function Tests (PFTs)
  • Physician Global Assessment
  • Patient Global Assessment

Safety was be assessed throughout the study and will include:.

  • Physical examinations (PEs)
  • Vital sign measurements
  • Weight measurements
  • Blood sample collection for hematology and chemistry; urinalysis
  • Electrocardiograms (ECGs)
  • Adverse event (AE) assessments
  • Concomitant medication assessments
  • Pregnancy testing for females of childbearing potential.

Reasons for discontinuation of treatment because of adverse events were documented. Careful monitoring of all adverse events was carried out. Dosing could be reduced 1 dose level. If the dose was not tolerated, then the participant was discontinued from the study. If there is an interruption of dosing, after 14 days the participant was discontinued from the study.

Participants were given a study drug diary to record the details of each dose of belumosudil 200 mg. Diaries were dispense/collected on each visit. Compliance with dosing was confirmed using participant diaries, which was examined at each visit by site staff to determine if dosing was as instructed per protocol and follow-up.

A 4-Week Safety Follow-up Visit occurred 28 days (± 3 days) after the last dose of study drug.

03

Conditions studied

  • Diffuse Cutaneous Systemic Sclerosis

Keywords

  • skin diseases
  • systemic sclerosis
  • phase 2
  • Scleroderma Health Assessment Questionnaire Disability Index
  • Modified Rodnan Skin Score
  • Combined Response Index in dcSSc (CRISS)
  • diffuse cutaneous systemic sclerosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female participants greater than or equal to (>=) 18 years old with the diagnosis of dcSSc according to the 2013 American College of Rheumatology and European League Against Rheumatism.
  2. Had disease duration (defined as interval from first non Raynaud disease manifestation) of less than or equal to (\<=) 6 years.
  3. Had mRSS of >=15 but \<=40.
  4. Had active disease as determined by the Principal Investigator within the 6 months prior to screening.
  5. Adequate organ and bone marrow functions evaluated during the 28 days prior to enrollment as follows:

    1. >= 1.5*10\^9/L
    2. count >= 100*10\^9/L
    3. Total \<= 1.0* (ULN)
    4. (ALT) and aspartate aminotransferase (AST), and serum creatinine \<= 1.5*ULN.
  6. Female participants of had a negative pregnancy test at screening. Females of childbearing potential were defined as sexually mature women without prior hysterectomy or who had any evidence of menses in the past 12 months. However, women who had been amenorrheic for 12 or more months were still considered to be of childbearing potential if the amenorrhea was possibly due to prior chemotherapy, anti-estrogens, or ovarian suppression.

    1. Women of childbearing potential (i.e., menstruating women) must had a negative urine pregnancy test (positive urine tests were to be confirmed by serum test) documented within the 24-hour period prior to the first dose of study drug.
    2. Sexually active women of childbearing potential enrolled in the study agreed to use two forms of accepted methods of during the course of the study and for 3 months after their last dose of study drug. Effective birth control includes (i) intrauterine device plus 1 barrier method; (ii) on stable doses of hormonal contraception for at least 3 months (e.g., oral, injectable, implant, transdermal) plus 1 barrier method; or (iii) 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm), or a vasectomized partner.
  7. For male participants who were sexually active and who were partners of premenopausal women: agreement to use 2 forms of contraception as in criterion number 6b above during the treatment period and for at least 3 months after the last dose of study drug.
  8. Male participants must not donate sperm for 3 months after last dose of study drug.
  9. Able to provide written prior to the performance of any study-specific procedures.

Exclusion criteria

Exclusion Criteria:

  1. Participants had interval using Fridericia's formula (QTcF) greater than 450 milliseconds.
  2. Ongoing use or current use of concomitant medication known to have the potential for QTc prolongation.
  3. Female participant who was pregnant or breastfed.
  4. Participated in another study with an drug within 28 days of study entry (for studies involving biologics, within 3 half-lives of the biologic).
  5. History or other evidence of severe illness or any other conditions that would make the participant, in the opinion of the Investigator, unsuitable for the study.
  6. Chronic heart failure with Classes II, III, or IV.
  7. Acute or chronic liver disease (e.g., cirrhosis).
  8. Positive (HIV) test.
  9. Active virus (HCV), virus (HBV), or positive whole blood tuberculin test.
  10. Diagnosed with any within 3 years of enrollment, with the exception of basal cell or completely resected squamous cell carcinoma of the skin, resected in situ cervical malignancy, resected breast ductal carcinoma in situ, or low risk prostate cancer after curative resection.
  11. Had previous exposure to belumosudil or known allergy/sensitivity to belumosudil, or any other Rho-associated Protein Kinase-2 (ROCK2) inhibitor.
  12. Scleroderma renal crisis within 4 months prior to enrollment.
  13. Forced vital capacity \<= 50% Predicted.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Belumosudil

    Participants received belumosudil 200 mg tablet orally PO, BID for 52 weeks.

    Drug: Belumosudil

Interventions

  • 10 participants with dcSSc received belumosudil 200 mg PO BID for 52 weeks

    Also known as: KD025

06

What researchers measure

Primary outcomes

  1. Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS) Score at Week 24

    CRISS components included the following domains: modified Rodnan skin score (mRSS), forced vital capacity (FVC) percent predicted, physician global assessment, patient global assessment, and scleroderma health assessment questionnaire disability-index (SHAQ-DI). An algorithm determines the predicted probability of improvement from Baseline by incorporating change in the mRSS, FVC percent predicted, physician and patient global assessments, and SHAQ-DI. The outcome is a continuous variable between 0.0 and 1.0 (0 to 100%). A higher score indicated greater probability of improvement. Participants are not considered improved if they develop new onset of renal crisis, new onset or worsening of lung fibrosis, new onset of pulmonary arterial hypertension, new onset of left ventricular failure during the trial. CRISS score greater than 60% is considered the minimally important difference.

    Time frame: Week 24

Secondary outcomes

  1. Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS) Score at Weeks 8, 16, 36, and 52

    CRISS components included the following domains: mRSS, FVC percent predicted, physician global assessment, patient global assessment, and SHAQ-DI. An algorithm determines the predicted probability of improvement from Baseline by incorporating change in the mRSS, FVC percent predicted, physician and patient global assessments, and SHAQ-DI. The outcome is a continuous variable between 0.0 and 1.0 (0 to 100%). A higher score indicated greater probability of improvement. Participants are not considered improved if they develop new onset of renal crisis, new onset or worsening of lung fibrosis, new onset of pulmonary arterial hypertension, new onset of left ventricular failure during the trial. CRISS score greater than 60% is considered the minimally important difference.

    Time frame: Week 8, 16, 36 and 52

  2. Modified Rodnan Skin Score (mRSS) at Week 24

    The mRSS is an accepted clinical measure of the skin thickness. The investigator assessed the thickening of the skin using the modified Rodnan Skin Score through simple palpation on 17 different skin sites in the fingers, hands, forearms, arms, feet, legs, and thighs (bilaterally) and face, chest, and abdomen (singly). Each skin site was rated on a 0 to 3 scale; where 0 = normal skin, 1 = mild thickness, 2 = moderate thickness, and 3 = severe thickness and unable to pinch. Individual skin scores in the 17 body areas were summed and defined as the total mRSS which ranged from 0 (no thickening) to 51 (severe thickening), where higher score indicated more severity of skin thickening/worst outcome.

    Time frame: Week 24

  3. Forced Vital Capacity (FVC) Level at Week 24

    FVC was the total amount of air (in liters) exhaled from the lungs during the lung function test measured by spirometer which assessed the change in lung function related to the disease status of an underlying interstitial lung disease.

    Time frame: Week 24

  4. Physician Global Assessment of Participant's Overall Health Using Visual Analogue Scale (VAS) Score at Week 24

    The Physician Global Assessment (reported by the physician) quantified the participant's overall health during the last week based on a VAS which ranged from 0 (extremely poor) to 100 (excellent). Higher score indicated better outcome.

    Time frame: Week 24

  5. Patient Global Assessment of Participant's Overall Health Using Visual Analogue Scale (VAS) Score at Week 24

    The Patient Global Assessment (reported by participant) quantified the participant's overall health during the last week based on a VAS which ranged from 0 (extremely poor) to 100 (excellent). Higher score indicated better outcome.

    Time frame: Week 24

  6. Scleroderma Health Assessment Questionnaire-Disability Index (SHAQ-DI) Total Score at Week 24

    SHAQ-DI included the general health assessment questionnaire-disability index (HAD-DI) assessment and 6 scleroderma-specific VAS items to explore the impact of participant's disease. The general HAD-DI assessment included 8 domains addressing scleroderma related manifestations that contribute to disability. It is a quality of life measure. For each question, level of difficulty was scored from 0 to 3, where 0=no difficulty, 1=some difficulty, 2=much difficulty, 3=unable to do. Some domains in the SHAQ are visual analog scales that are measured first and then changed to a 0-3 scale. SHAQ-DI total score was computed as the sum of domain scores divided by the number of domains answered and it ranged from 0 (no difficulty) to 3 (maximum difficulty), where higher score indicated greater disability/worse functionality.

    Time frame: Week 24

  7. Change From Baseline in Modified Rodnan Skin Thickness Score (mRSS) at Weeks 8, 16, 36, and 52

    The mRSS is an accepted clinical measure of the skin thickness. The investigator assessed the thickening of the skin using the modified Rodnan Skin Score through simple palpation on 17 different skin sites in the fingers, hands, forearms, arms, feet, legs, and thighs (bilaterally) and face, chest, and abdomen (singly). Each skin site was rated on a 0 to 3 scale; where 0 = normal skin, 1 = mild thickness, 2 = moderate thickness, and 3 = severe thickness and unable to pinch. Individual skin scores in the 17 body areas were summed and defined as the total mRSS which ranged from 0 (no thickening) to 51 (severe thickening), where higher score indicated more severity of skin thickening/worst outcome. A negative change from baseline demonstrates improvement.

    Time frame: Baseline, Week 8, 16, 36 and 52

  8. Change From Baseline in Forced Vital Capacity (FVC) Level at Weeks 8, 16, 36, and 52

    FVC was the total amount of air (in liters) exhaled from the lungs during the lung function test measured by spirometer which assessed the change in lung function related to the disease status of an underlying interstitial lung disease. Change from Baseline was calculated by subtracting Baseline value from specified values at each reported week (Week 8, 16, 36 and 52).

    Time frame: Baseline, Week 8, 16, 36 and 52

  9. Change From Baseline in Physician Global Assessment (Reported by the Physician) Quantified of Participant's Overall Health Using Visual Analogue Scale (VAS) Score at Weeks 8, 16, 36, and 52

    The Physician Global Assessment (reported by the physician) quantified the participant's overall health during the last week based on a VAS which ranged from 0 (extremely poor) to 100 (excellent). Higher score indicated better outcome. A positive change from Baseline demonstrated improvement.

    Time frame: Baseline, Week 8, 16, 36 and 52

  10. Change From Baseline in Patient Global Assessment of Participant's Overall Health Using Visual Analogue Scale (VAS) Score at Weeks 8, 16, 36, and 52

    The Patient Global Assessment (reported by participant) quantified the participant's overall health during the last week based on a VAS which ranged from 0 (extremely poor) to 100 (excellent). Higher score indicated better outcome. A positive change from Baseline demonstrated improvement.

    Time frame: Baseline, Week 8, 16, 36 and 52

  11. Change From Baseline in Scleroderma Health Assessment Questionnaire-Disability Index (SHAQ-DI) Total Score at Weeks 8, 16, 36, and 52

    SHAQ-DI VAS included the general HAD-DI assessment and 6 scleroderma-specific VAS items to explore the impact of participant's disease. The general HAD-DI assessment included 8 domains addressing scleroderma related manifestations that contribute to disability. It is a quality of life measure. Each activity category consisted of 2 to 3 items. For each question, level of difficulty was scored from 0 to 3, where 0=no difficulty, 1=some difficulty, 2=much difficulty, 3=unable to do. Some domains in the SHAQ are visual analog scales that are measured first and then changed to a 0-3 scale. SHAQ-DI total score was computed as the sum of domain scores divided by the number of domains answered and it ranged from 0 (no difficulty) to 3 (maximum difficulty), where higher score indicated greater disability/worse functionality.

    Time frame: Baseline, Week 8, 16, 36 and 52

  12. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    Adverse event (AE): any untoward medical occurrence in a participant who received investigational medicinal product (IMP) without regard to possibility of causal relationship with the treatment. TEAEs: AEs that developed/worsened or became serious during treatment-emergent period (time of first dose administration of study medication up to 28 days after last dose). Serious AE (SAE): any untoward medical occurrence resulted in any of following outcomes: death, life-threatening, required initial/prolonged in-patient hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event.

    Time frame: From first dose administration (i.e., Day 1) of study medication up to 28 days after last dose (i.e., up to 57.5 weeks)

07

Results

Posted Jun 5, 2023
Limitations and caveats
Due to slow enrollment and strategic consideration, Sponsor decided to terminate the study and the termination was not driven by any safety concerns.

Participant flow

The study was conducted at 6 active sites. A total of 11 participants were screened between 03 Mar 2021 and 23 Nov 2021, of which 1 participant was screen failure due to not meeting eligibility criteria.

Participant flow — Overall Study
MilestoneBelumosudil
Started10
Completed4
Not completed6
Withdrew: Adverse event3
Withdrew: Death1
Withdrew: Progressive disease1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryCombined Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS) Score at Week 24

CRISS components included the following domains: modified Rodnan skin score (mRSS), forced vital capacity (FVC) percent predicted, physician global assessment, patient global assessment, and scleroderma health assessment questionnaire disability-index (SHAQ-DI). An algorithm determines the predicted probability of improvement from Baseline by incorporating change in the mRSS, FVC percent predicted, physician and patient global assessments, and SHAQ-DI. The outcome is a continuous variable between 0.0 and 1.0 (0 to 100%). A higher score indicated greater probability of improvement. Participants are not considered improved if they develop new onset of renal crisis, new onset or worsening of lung fibrosis, new onset of pulmonary arterial hypertension, new onset of left ventricular failure during the trial. CRISS score greater than 60% is considered the minimally important difference.

Time frame:
Week 24
Reported as:
Mean · score on a scale
Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS) Score at Week 24
score on a scaleBelumosudil
Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS) Score at Week 246.65 ± 12.926
SecondaryCombined Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS) Score at Weeks 8, 16, 36, and 52

CRISS components included the following domains: mRSS, FVC percent predicted, physician global assessment, patient global assessment, and SHAQ-DI. An algorithm determines the predicted probability of improvement from Baseline by incorporating change in the mRSS, FVC percent predicted, physician and patient global assessments, and SHAQ-DI. The outcome is a continuous variable between 0.0 and 1.0 (0 to 100%). A higher score indicated greater probability of improvement. Participants are not considered improved if they develop new onset of renal crisis, new onset or worsening of lung fibrosis, new onset of pulmonary arterial hypertension, new onset of left ventricular failure during the trial. CRISS score greater than 60% is considered the minimally important difference.

Time frame:
Week 8, 16, 36 and 52
Reported as:
Mean · score on a scale
Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS) Score at Weeks 8, 16, 36, and 52
score on a scaleBelumosudil
Week 813.97 ± 24.657
Week 1620.48 ± 41.654
Week 3622.38 ± 44.715
Week 5225.49 ± 49.674
SecondaryModified Rodnan Skin Score (mRSS) at Week 24

The mRSS is an accepted clinical measure of the skin thickness. The investigator assessed the thickening of the skin using the modified Rodnan Skin Score through simple palpation on 17 different skin sites in the fingers, hands, forearms, arms, feet, legs, and thighs (bilaterally) and face, chest, and abdomen (singly). Each skin site was rated on a 0 to 3 scale; where 0 = normal skin, 1 = mild thickness, 2 = moderate thickness, and 3 = severe thickness and unable to pinch. Individual skin scores in the 17 body areas were summed and defined as the total mRSS which ranged from 0 (no thickening) to 51 (severe thickening), where higher score indicated more severity of skin thickening/worst outcome.

Time frame:
Week 24
Reported as:
Mean · score on a scale
Modified Rodnan Skin Score (mRSS) at Week 24
score on a scaleBelumosudil
Modified Rodnan Skin Score (mRSS) at Week 2424.2 ± 11.16
SecondaryForced Vital Capacity (FVC) Level at Week 24

FVC was the total amount of air (in liters) exhaled from the lungs during the lung function test measured by spirometer which assessed the change in lung function related to the disease status of an underlying interstitial lung disease.

Time frame:
Week 24
Reported as:
Mean · liters
Forced Vital Capacity (FVC) Level at Week 24
litersBelumosudil
Forced Vital Capacity (FVC) Level at Week 2485.7 ± 25.28
SecondaryPhysician Global Assessment of Participant's Overall Health Using Visual Analogue Scale (VAS) Score at Week 24

The Physician Global Assessment (reported by the physician) quantified the participant's overall health during the last week based on a VAS which ranged from 0 (extremely poor) to 100 (excellent). Higher score indicated better outcome.

Time frame:
Week 24
Reported as:
Mean · score on a scale
Physician Global Assessment of Participant's Overall Health Using Visual Analogue Scale (VAS) Score at Week 24
score on a scaleBelumosudil
Physician Global Assessment of Participant's Overall Health Using Visual Analogue Scale (VAS) Score at Week 2461.2 ± 30.32
SecondaryPatient Global Assessment of Participant's Overall Health Using Visual Analogue Scale (VAS) Score at Week 24

The Patient Global Assessment (reported by participant) quantified the participant's overall health during the last week based on a VAS which ranged from 0 (extremely poor) to 100 (excellent). Higher score indicated better outcome.

Time frame:
Week 24
Reported as:
Mean · score on a scale
Patient Global Assessment of Participant's Overall Health Using Visual Analogue Scale (VAS) Score at Week 24
score on a scaleBelumosudil
Patient Global Assessment of Participant's Overall Health Using Visual Analogue Scale (VAS) Score at Week 2451.3 ± 34.54
SecondaryScleroderma Health Assessment Questionnaire-Disability Index (SHAQ-DI) Total Score at Week 24

SHAQ-DI included the general health assessment questionnaire-disability index (HAD-DI) assessment and 6 scleroderma-specific VAS items to explore the impact of participant's disease. The general HAD-DI assessment included 8 domains addressing scleroderma related manifestations that contribute to disability. It is a quality of life measure. For each question, level of difficulty was scored from 0 to 3, where 0=no difficulty, 1=some difficulty, 2=much difficulty, 3=unable to do. Some domains in the SHAQ are visual analog scales that are measured first and then changed to a 0-3 scale. SHAQ-DI total score was computed as the sum of domain scores divided by the number of domains answered and it ranged from 0 (no difficulty) to 3 (maximum difficulty), where higher score indicated greater disability/worse functionality.

Time frame:
Week 24
Reported as:
Mean · score on a scale
Scleroderma Health Assessment Questionnaire-Disability Index (SHAQ-DI) Total Score at Week 24
score on a scaleBelumosudil
Scleroderma Health Assessment Questionnaire-Disability Index (SHAQ-DI) Total Score at Week 241.750 ± 1.072
SecondaryChange From Baseline in Modified Rodnan Skin Thickness Score (mRSS) at Weeks 8, 16, 36, and 52

The mRSS is an accepted clinical measure of the skin thickness. The investigator assessed the thickening of the skin using the modified Rodnan Skin Score through simple palpation on 17 different skin sites in the fingers, hands, forearms, arms, feet, legs, and thighs (bilaterally) and face, chest, and abdomen (singly). Each skin site was rated on a 0 to 3 scale; where 0 = normal skin, 1 = mild thickness, 2 = moderate thickness, and 3 = severe thickness and unable to pinch. Individual skin scores in the 17 body areas were summed and defined as the total mRSS which ranged from 0 (no thickening) to 51 (severe thickening), where higher score indicated more severity of skin thickening/worst outcome. A negative change from baseline demonstrates improvement.

Time frame:
Baseline, Week 8, 16, 36 and 52
Reported as:
Mean · score on a scale
Change From Baseline in Modified Rodnan Skin Thickness Score (mRSS) at Weeks 8, 16, 36, and 52
score on a scaleBelumosudil
Week 8-1.2 ± 2.82
Week 16-1.0 ± 4.86
Week 360.2 ± 6.57
Week 52-1.0 ± 8.98
SecondaryChange From Baseline in Forced Vital Capacity (FVC) Level at Weeks 8, 16, 36, and 52

FVC was the total amount of air (in liters) exhaled from the lungs during the lung function test measured by spirometer which assessed the change in lung function related to the disease status of an underlying interstitial lung disease. Change from Baseline was calculated by subtracting Baseline value from specified values at each reported week (Week 8, 16, 36 and 52).

Time frame:
Baseline, Week 8, 16, 36 and 52
Reported as:
Mean · liters
Change From Baseline in Forced Vital Capacity (FVC) Level at Weeks 8, 16, 36, and 52
litersBelumosudil
Week 80.8 ± 4.15
Week 162.9 ± 4.85
Week 363.3 ± 9.32
Week 520.8 ± 15.52
SecondaryChange From Baseline in Physician Global Assessment (Reported by the Physician) Quantified of Participant's Overall Health Using Visual Analogue Scale (VAS) Score at Weeks 8, 16, 36, and 52

The Physician Global Assessment (reported by the physician) quantified the participant's overall health during the last week based on a VAS which ranged from 0 (extremely poor) to 100 (excellent). Higher score indicated better outcome. A positive change from Baseline demonstrated improvement.

Time frame:
Baseline, Week 8, 16, 36 and 52
Reported as:
Mean · score on a scale
Change From Baseline in Physician Global Assessment (Reported by the Physician) Quantified of Participant's Overall Health Using Visual Analogue Scale (VAS) Score at Weeks 8, 16, 36, and 52
score on a scaleBelumosudil
Week 80.1 ± 19.04
Week 163.5 ± 19.72
Week 367.6 ± 29.23
Week 5212.0 ± 32.22
SecondaryChange From Baseline in Patient Global Assessment of Participant's Overall Health Using Visual Analogue Scale (VAS) Score at Weeks 8, 16, 36, and 52

The Patient Global Assessment (reported by participant) quantified the participant's overall health during the last week based on a VAS which ranged from 0 (extremely poor) to 100 (excellent). Higher score indicated better outcome. A positive change from Baseline demonstrated improvement.

Time frame:
Baseline, Week 8, 16, 36 and 52
Reported as:
Mean · score on a scale
Change From Baseline in Patient Global Assessment of Participant's Overall Health Using Visual Analogue Scale (VAS) Score at Weeks 8, 16, 36, and 52
score on a scaleBelumosudil
Week 8-5.6 ± 27.68
Week 16-7.2 ± 17.38
Week 36-3.0 ± 45.54
Week 52-20.0 ± 22.82
SecondaryChange From Baseline in Scleroderma Health Assessment Questionnaire-Disability Index (SHAQ-DI) Total Score at Weeks 8, 16, 36, and 52

SHAQ-DI VAS included the general HAD-DI assessment and 6 scleroderma-specific VAS items to explore the impact of participant's disease. The general HAD-DI assessment included 8 domains addressing scleroderma related manifestations that contribute to disability. It is a quality of life measure. Each activity category consisted of 2 to 3 items. For each question, level of difficulty was scored from 0 to 3, where 0=no difficulty, 1=some difficulty, 2=much difficulty, 3=unable to do. Some domains in the SHAQ are visual analog scales that are measured first and then changed to a 0-3 scale. SHAQ-DI total score was computed as the sum of domain scores divided by the number of domains answered and it ranged from 0 (no difficulty) to 3 (maximum difficulty), where higher score indicated greater disability/worse functionality.

Time frame:
Baseline, Week 8, 16, 36 and 52
Reported as:
Mean · score on a scale
Change From Baseline in Scleroderma Health Assessment Questionnaire-Disability Index (SHAQ-DI) Total Score at Weeks 8, 16, 36, and 52
score on a scaleBelumosudil
Week 8-0.069 ± 0.208
Week 16-0.036 ± 0.312
Week 36-0.075 ± 0.244
Week 520.031 ± 0.483
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

Adverse event (AE): any untoward medical occurrence in a participant who received investigational medicinal product (IMP) without regard to possibility of causal relationship with the treatment. TEAEs: AEs that developed/worsened or became serious during treatment-emergent period (time of first dose administration of study medication up to 28 days after last dose). Serious AE (SAE): any untoward medical occurrence resulted in any of following outcomes: death, life-threatening, required initial/prolonged in-patient hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event.

Time frame:
From first dose administration (i.e., Day 1) of study medication up to 28 days after last dose (i.e., up to 57.5 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
ParticipantsBelumosudil
Any TEAEs10
Any TESAEs4

Adverse events

Collected over From first dose administration (i.e., Day 1) of study medication up to 28 days after last dose (i.e., up to 57.5 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Belumosudil1/10 (10%)4/10 (40%)10/10 (100%)
Most frequent serious events
Most frequent serious events
EventBelumosudil
DehydrationMetabolism and nutrition disorders1/10
Intraductal Proliferative Breast LesionNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/10
SyncopeNervous system disorders1/10
Acute Kidney InjuryRenal and urinary disorders1/10
DyspnoeaRespiratory, thoracic and mediastinal disorders1/10
HypotensionVascular disorders1/10
ShockVascular disorders1/10
Most frequent other events
Showing 10 of 63
Most frequent other events
EventBelumosudil
DiarrhoeaGastrointestinal disorders6/10
NauseaGastrointestinal disorders6/10
VomitingGastrointestinal disorders6/10
FatigueGeneral disorders5/10
HeadacheNervous system disorders4/10
PruritusSkin and subcutaneous tissue disorders3/10
PhotophobiaEye disorders2/10
Gastrooesophageal Reflux DiseaseGastrointestinal disorders2/10
Covid-19Infections and infestations2/10
Coronavirus InfectionInfections and infestations2/10

Baseline characteristics

Analysis was performed on modified intent to treat (mITT) population which included all participants who received at least 1 dose of belumosudil 200 mg.

Age, Continuous
Age, Continuous(years)Belumosudil
Mean46.9 ± 7.31
Sex: Female, Male
Sex: Female, Male(Participants)Belumosudil
Female10
Male0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Belumosudil
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American2
White8
More than one race0
Unknown or Not Reported0
08

Study locations

6 sites
  • University of California, Los Angeles Medical Center_Site number 104
    Los Angeles, California 90095, United States
  • Yale University School of Medicine_Site number 140
    New Haven, Connecticut 06519, United States
  • Northwestern University_Site number 124
    Chicago, Illinois 60611, United States
  • Columbia University Medical Center_Site number 086
    New York, New York 10032, United States
  • University of Utah_Site number 048
    Salt Lake City, Utah 84132, United States
  • Virginia Mason Medical Center_Site number 145
    Seattle, Washington 98101, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized, and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in May 2022, 14 months.

Results were first posted in Jun 2023, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2020
First posted
Dec 23, 2020
StartActual
Mar 3, 2021
Primary completionActual
May 10, 2022
CompletionActual
Dec 19, 2022
Results first posted
Jun 5, 2023
Last update
Jun 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04680975
Responsible party
Sponsor
First posted
Dec 23, 2020
Start date
Mar 3, 2021
Primary completion
May 10, 2022
Completion
Dec 19, 2022
Results posted
Jun 5, 2023
Last update
Jun 5, 2023

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belumosudil

Start the discussion